全文获取类型
收费全文 | 7697篇 |
免费 | 1012篇 |
国内免费 | 120篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 1002篇 |
妇产科学 | 56篇 |
基础医学 | 576篇 |
口腔科学 | 85篇 |
临床医学 | 552篇 |
内科学 | 2003篇 |
皮肤病学 | 206篇 |
神经病学 | 151篇 |
特种医学 | 133篇 |
外科学 | 2884篇 |
综合类 | 251篇 |
预防医学 | 181篇 |
眼科学 | 88篇 |
药学 | 252篇 |
中国医学 | 33篇 |
肿瘤学 | 340篇 |
出版年
2023年 | 248篇 |
2022年 | 162篇 |
2021年 | 319篇 |
2020年 | 494篇 |
2019年 | 569篇 |
2018年 | 520篇 |
2017年 | 460篇 |
2016年 | 393篇 |
2015年 | 333篇 |
2014年 | 502篇 |
2013年 | 594篇 |
2012年 | 402篇 |
2011年 | 426篇 |
2010年 | 364篇 |
2009年 | 330篇 |
2008年 | 331篇 |
2007年 | 310篇 |
2006年 | 323篇 |
2005年 | 290篇 |
2004年 | 228篇 |
2003年 | 183篇 |
2002年 | 167篇 |
2001年 | 135篇 |
2000年 | 96篇 |
1999年 | 86篇 |
1998年 | 48篇 |
1997年 | 47篇 |
1996年 | 37篇 |
1995年 | 53篇 |
1994年 | 56篇 |
1993年 | 43篇 |
1992年 | 54篇 |
1991年 | 31篇 |
1990年 | 24篇 |
1989年 | 16篇 |
1988年 | 23篇 |
1987年 | 21篇 |
1986年 | 25篇 |
1985年 | 23篇 |
1984年 | 11篇 |
1983年 | 8篇 |
1982年 | 15篇 |
1981年 | 8篇 |
1980年 | 4篇 |
1979年 | 5篇 |
1978年 | 2篇 |
1977年 | 3篇 |
1976年 | 3篇 |
1975年 | 1篇 |
1974年 | 2篇 |
排序方式: 共有8829条查询结果,搜索用时 15 毫秒
21.
Jin Ge Emily R. Perito John Bucuvalas Richard Gilroy Evelyn K. Hsu John P. Roberts Jennifer C. Lai 《American journal of transplantation》2020,20(4):1116-1124
Split liver transplantation (SLT) is 1 strategy for maximizing the number of deceased donor liver transplants. Recent reports suggest that utilization of SLT in the United States remains low. We examined deceased donor offers that were ultimately split between 2010 and 2014. SLTs were categorized as “primary” and “secondary” transplants. We analyzed allocation patterns and used logistic regression to evaluate factors associated with secondary split discard. Four hundred eighteen livers were split: 54% from adult, 46% from pediatric donors. Of the 227 adult donor livers split, 61% met United Network for Organ Sharing “optimal” split criteria. A total of 770 recipients (418 primary and 352 secondary) were transplanted, indicating 16% discard. Ninety‐two percent of the 418 primary recipients were children, and 47% were accepted on the first offer. Eighty‐seven percent of the 352 secondary recipients were adults, and 7% were accepted on the first offer. Of the 352 pairs, 99% were transplanted in the same region, 36% at the same center. In logistic regression, shorter donor height was associated with secondary discard (odds ratio 0.97 per cm, 95% CI 0.94‐1.00, P = .02). SLT volume by center was not predictive of secondary discard. Current policy proposals that incentivize SLT in the United States could increase the number of transplants to children and adults. 相似文献
22.
23.
24.
Aliyah Hussein Kiran Sran Imran Ali Janine Woellner Helen Wilcox Stephen D. Marks Helen Jones Chris Callaghan 《Pediatric transplantation》2020,24(4)
Transplant ureteric stent insertion reduces the incidence of MUCs, but it is not known whether routine PSRGU is needed to detect unmasked MUCs. This study evaluated whether routine PSRGU in the pRTR is a useful tool to identify MUCs before they become clinically apparent. A retrospective analysis was undertaken of the clinical outcomes following elective stent removal from pediatric kidney‐only transplant recipients at two London centers between 2012 and 2016. Our policy was to perform PSRGU either routinely or urgently if there were concerning symptoms or biochemical evidence of renal allograft dysfunction. Elective stent removal was performed in 86% (97 of 113 pRTR), and 75 (77%) of whom had routine PSRGU at a median (IQR) of 6 (2‐8) days after stent removal. There were changes to management in 3 (4%) of pRTR with PSRGU identifying no MUC. Nineteen patients (25%) had urgent PSRGU, most commonly due to renal allograft dysfunction, at a median (IQR) of 5.5 (2.7‐12.3) days after stent removal. Of these, two pRTR required ureteric intervention. For our current practice of removing transplant stents at 4‐6 weeks post‐transplantation, our study has found no evidence to support routine PSRGU after elective stent removal. 相似文献
25.
26.
Erik L. Frandsen Jessica Otero Joe C. Rutledge Mariska S. Kemna Erin L. Albers Borah J. Hong Yuk M. Law Joshua M. Friedland‐Little 《Pediatric transplantation》2020,24(1)
Bortezomib is approved for the treatment of multiple myeloma but increasingly used in heart transplant (HTx) recipients with antibody‐mediated rejection (AMR). Severe pulmonary toxicity is a rare complication in multiple myeloma patients treated with bortezomib, but has not been described in a solid organ transplant recipient. A 20‐year‐old man 7 years post‐HTx presented with acute rejection with hemodynamic compromise. Endomyocardial biopsy showed mixed rejection (ISHLT grade 2R‐3R acute cellular rejection (ACR) and pAMR 1 (I+) with diffuse C4d staining). Two new high MFI circulating MHC class‐II donor‐specific antibodies (DSA) were detected. Treatment included corticosteroids, antithymocyte globulin, plasmapheresis, IVIG, rituximab, and bortezomib (1.3 mg/m2). Due to rebound in DSA, a second course of bortezomib was started. Thrombocytopenia and peripheral neuropathy prompted a 50% dose reduction during the 2nd course. Shortly after the 3rd reduced dose, the patient developed hypoxemic respiratory failure. Bronchoscopy revealed pulmonary hemorrhage with negative infectious studies. Chest CT showed bilateral parenchymal disease with bronchiectasis and alveolar bleeding. Despite treatment with high‐dose steroids, severe ARDS ensued with multisystem organ failure. The patient expired 23 days after the final dose of bortezomib. Post‐mortem lung histology revealed diffuse alveolar damage, pulmonary fibrosis, and hemorrhage. Cardiac histology showed resolving/residual ACR 1R and pAMR 1 (I+). While rare, bortezomib‐induced lung toxicity (BILT) can occur in HTx recipients and can carry a high risk of mortality. Drug reaction and immediate drug withdrawal should be considered in patients who develop respiratory symptoms, though optimal management of BILT is unclear. 相似文献
27.
28.
29.